NOT-CA-22-093: Notice to Extend Expiration Date for PAR-20-277: Secondary Analysis and Integration of Existing Data to Elucidate the Genetic Architecture of Cancer Risk and Related Outcomes (R21 Clinical Trial Not Allowed)

Notice to Extend Expiration Date for PAR-20-277: Secondary Analysis and Integration of Existing Data to Elucidate the Genetic Architecture of Cancer Risk and Related Outcomes (R21 Clinical Trial Not Allowed)

Notice Number:

NOT-CA-22-093

Key Dates

Release Date:

June 17, 2022

Related Announcements

PAR-20-277 - Secondary Analysis and Integration of Existing Data to Elucidate the Genetic Architecture of Cancer Risk and Related Outcomes (R21 Clinical Trial Not Allowed)

Issued by

National Cancer Institute (NCI)

National Institute of Dental and Craniofacial Research (NIDCR)

Purpose

The purpose of this Notice is to extend the expiration date for PAR-20-277 “Secondary Analysis and Integration of Existing Data to Elucidate the Genetic Architecture of Cancer Risk and Related Outcomes (R21 Clinical Trial Not Allowed).”

PAR-20-277 will now expire on January 8, 2023.

The following section has been changed:

Part 1. Overview Information, Key Dates

Currently reads:

Expiration Date: September 08, 2022

Corrected to read (in italics):

Expiration Date: January 08, 2023

All other aspects of this FOA remain unchanged.

Inquiries

Please direct all inquiries to:

Melissa Rotunno, Ph.D.
National Cancer Institute (NCI)
Telephone: 240-276-7245
Email: [email protected]